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Background:  The DCCT showed that improving glycaemic control reduces risk of long-term 
complications but increases frequency of severe hypoglycaemia. A 5-day training course in 
flexible, intensive insulin management with unrestricted diet in Germany and Austria 
improved glycaemic control without increasing severe hypoglycaemia.  Aim:  To assess the 
feasibility of recruiting people to the UK Dose Adjustment For Normal Eating (DAFNE) trial 
of this approach. 
 
Methods:  1016 people with Type 1 diabetes (HbA1c 7.5-12%) registered with diabetes 
services at King's College Hospital, London, Northern General Hospital, Sheffield and 
Northumbria Healthcare Trust were invited to participate. 583 (57.4%) returned feedback 
forms. Analysis compared the multiple-choice responses of 299 volunteers and 188 non-
volunteers. 
 
Results:  Significant differences between volunteers and non-volunteers were identified for 
7 of 9 reasons for "interest" and 2 of 10 reasons for "concern" about DAFNE. There were 
no between-centre differences. Most commonly endorsed reasons for "interest" were 
preserving long-term health, improving glycaemic control and increasing dietary freedom. 
Most frequently indicated reasons for not volunteering were finding time to attend and 
satisfaction with current treatment (despite sub-optimal HbA1c). Even those not volunteering 
perceived benefits. 
 
Conclusions:  People with Type 1 diabetes are likely to participate in future DAFNE 
initiatives, encouraged by prospects of improving glycaemic control and long-term health, 
together with improvements in quality of life due to increased dietary freedom. Improved 
patient information and evidence for the success of the initial trial are likely to increase 
future recruitment to DAFNE. 
 
 
